Drug Trial Radar · NCT02601235
Efficacy and Safety of Pediatric Drugs in Nasal Congestion
Last checked: Nov 19, 2026Latest source record: Oct 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
292
Actual
Start
Jan 16, 2018
Primary completion
Aug 3, 2018
Study completion Apr 3, 2019
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Nov 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of the Naridrin in improving nasal congestion.
Conditions
- Nasal Congestion
Interventions
NaridrinDrug
Naridrin® : 2 drops in each nostril once daily as prescription
AfrinDrug
2 pumps in each nostril every 12 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relief of Nasal CongestionTime frame: 2 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Faculdade de Medicina do ABC
Santo André, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.